Anesthesia with 3% sevoflurane 2 h daily for 3 days in P6 wild-type mice decreases P-GSK3β(ser9) levels, but does not alter the levels of GSK3β and P-GSK3β(tyr279/tyr216), in hippocampus of the mice. (A) Anesthesia with 3% sevoflurane 2 h daily for 3 days in P6 mice decreases the levels of P-GSK3β(ser9) in the hippocampus of the mice as compared with the control condition. There is no significant difference in β-actin levels in the hippocampus of the mice between the sevoflurane anesthesia and control condition. (B) Quantification of the Western blot shows that the sevoflurane anesthesia decreases P-GSK3β(ser9) levels as compared with control condition. (C) Anesthesia with 3% sevoflurane 2 h daily for 3 days in P6 mice does not significantly alter the GSK3β levels in the hippocampus of the mice as compared with the control condition. There is no significant difference in β-actin levels in the hippocampus of the mice between the sevoflurane anesthesia and control condition. (D) Quantification of the Western blot shows that the sevoflurane anesthesia does not significantly alter the GSK3β levels as compared with the control condition. (E) Quantification of the Western blot (A and C) shows that the sevoflurane anesthesia decreases the ratio of P-GSK3β(ser9)/GSK3β as compared with the control condition. (F) Anesthesia with 3% sevoflurane 2 h daily for 3 days in P6 mice does not significantly alter the P-GSK3β(tyr279/tyr216) levels in the hippocampus of the mice as compared with the control condition. There is no significant difference in β-actin levels in the hippocampus of the mice between the sevoflurane anesthesia and control condition. (G) Quantification of the Western blot (F) shows that the sevoflurane anesthesia does not significantly alter the P-GSK3β(tyr279/tyr216) levels as compared with the control condition. GSK-3β = glycogen synthase kinase 3β; N.S. = nonsignificant; P = phosphorylated; ser9 = serine 9; tyr216 = tyrosine 216; tyr279 = tyrosine 279. **P < 0.01; N = 6 in each group.